NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
0.4600
+0.0410 (9.79%)
At close: Apr 25, 2025, 4:00 PM
0.4900
+0.0300 (6.52%)
Pre-market: Apr 28, 2025, 5:44 AM EDT
NextCure Employees
NextCure had 43 employees as of December 31, 2024. The number of employees decreased by 39 or -47.56% compared to the previous year.
Employees
43
Change (1Y)
-39
Growth (1Y)
-47.56%
Revenue / Employee
n/a
Profits / Employee
-$1,294,279
Market Cap
12.88M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
NXTC News
- 23 days ago - NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 7 weeks ago - NextCure Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewsWire
- 3 months ago - NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - GlobeNewsWire
- 4 months ago - NextCure Announces Acceptance of IND Application for LNCB74 - GlobeNewsWire
- 5 months ago - NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 5 months ago - Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta - GlobeNewsWire
- 6 months ago - NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 6 months ago - NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting - GlobeNewsWire